BFS
ANIX icon

Bradley Foster & Sargent’s Anixa Biosciences ANIX Stock Holding History

Bradley Foster & Sargent’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,263
Closed -$66.9K – 537
2025
Q2 		$66.9K Buy
+20,263
New +$57.9K ﹤0.01% 535

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bradley Foster & Sargent's ANIX Position: Q3 2025 in Review

Bradley Foster & Sargent sold out of Anixa Biosciences (ANIX) in Q3 2025, closing a stake of 20,263 shares — an estimated $66.9K sold.

Bradley Foster & Sargent first reported a position in ANIX in Q2 2025 and held it in 1 quarter. The position peaked at $66.9K in Q2 2025. 66 funds tracked by Wall St. Rank hold ANIX as of Q3 2025.

  • Bradley Foster & Sargent reported no remaining Anixa Biosciences position as of Q3 2025 after selling out during the quarter.
  • Bradley Foster & Sargent sold 20,263 Anixa Biosciences shares in Q3 2025, an estimated $66.9K.
  • Bradley Foster & Sargent first reported a position in Anixa Biosciences in Q2 2025 and held it in 1 quarter.
  • Bradley Foster & Sargent's Anixa Biosciences position peaked at $66.9K in Q2 2025.
  • 66 funds tracked by Wall St. Rank held Anixa Biosciences as of Q3 2025.

Based on Bradley Foster & Sargent's 13F filing for Q3 2025, filed 10 Nov 2025.